Abstract: Therapeutic agent delivery devices are provided. Aspects of the devices include an active agent composition and an actuator configured to deliver the active agent composition to a target delivery site. In some instances, aspects of the devices include a syringe comprising a viscous active agent composition, a needle operably coupled to the syringe and an actuator configured to deliver viscous active agent composition from the syringe through the needed to a target delivery site, such as an intravitreal site. In some instances, aspects of the devices include a sleeve comprising a solid formulation of the active agent; a needle operably coupled to the sleeve; and an actuator configured to move the solid formulation from the sleeve and through the needle, e.g., to an intravitreal location.

Abstract: Therapeutic agent delivery devices are provided. Aspects of the devices include a syringe that is not surface sterilized, a tip that includes a sterile tissue contacting surface and a needle operably coupled to the syringe and the tip. Also provided are methods of using the devices.

Abstract: An ophthalmic lens that includes a lens material having two opposing curved surfaces, the curved surfaces defining a lens axis; and a light scattering region surrounding a clear aperture. The clear aperture and the light scattering region are substantially centered on the lens axis, and the light scattering region has a plurality of spaced apart scattering centers (e.g., on a lens surface and/or embedded in the lens material) sized and shaped to scatter incident light, the scattering centers being arranged in a pattern that includes a random variation in spacing between adjacent dots and/or a random variation in dot size.

Abstract: Methods and compositions are provided for intravitreally delivering a polynucleotide to cone photoreceptors. Aspects of the methods include injecting a recombinant adeno-associated virus comprising a polynucleotide of interest into the vitreous of the eye. These methods and compositions find particular use in treating ocular disorders associated with cone dysfunction and/or death.

Abstract: An ophthalmic lens that includes a lens material having two opposing curved surfaces, the curved surfaces defining a lens axis; and a light scattering region surrounding a clear aperture. The clear aperture and the light scattering region are substantially centered on the lens axis, and the light scattering region has a plurality of spaced apart scattering centers (e.g., on a lens surface and/or embedded in the lens material) sized and shaped to scatter incident light, the scattering centers being arranged in a pattern that includes a random variation in spacing between adjacent dots and/or a random variation in dot size.

Abstract: Therapeutic agent delivery devices having integrated pain mitigation are provided. Aspects of the devices include a therapeutic agent delivery system; and an actuator component, where the therapeutic agent delivery system is present in a receiving space of the actuator component. The therapeutic agent delivery system includes dmg container, a needle and a tissue contacting tip. The actuator component includes a therapeutic agent delivery system actuator and a pain mitigation system. Also provided are methods of using the devices, as well as kits that include various components of the systems.

Abstract: Techniques for evaluating and reducing myopiagenic effects of electronic displays are disclosed.

Abstract: Active agent delivery devices are provided. Aspects of the devices include an active agent delivery component having an active agent delivery system; and an actuator component, where the active agent delivery component is release-ably engaged to the actuator component. The actuator component includes an active agent delivery system actuator. Either or both components may contain one or more elements of a pain mitigation system and/or a smart device system, e.g., an identifier and identifier reader. Also provided are methods of using the devices.

Abstract: Evaluating differential stimulation of L and M cones in a viewer's eye by an image displayed on a color display includes receiving information about the spectral emission properties of the display; receiving image data; determining an achromatic component of the image based on image data and information about the spectral emission properties of the display, the achromatic component representing differential stimulation of L and M cones due to contrast variations in the image; determining a chromatic component of the image based image data and information about the spectral emission properties of the color display, this component representing differential stimulation of L and M cones due to spectral content of the image; and evaluating the differential stimulation of L and M cones based on the chromatic and achromatic components.

Abstract: Various techniques can be used to evaluate and reduce myopiagenic effects of electronic displays are disclosed. In one example, uncorrected image data corresponding to at least one uncorrected frame is assessed by identifying pixels having a red hue in the uncorrected frame(s). Modified image data is provided based on the uncorrected image data and the assessment. The modified image data corresponds to at least one corrected frame corresponding to the at least one uncorrected frame. Corrected frames are displayed, where one or more red-hued pixels in a corrected frame has a reduced degree of red saturation compared to the corresponding pixel in the uncorrected frame. The degree of red saturation in the red-hued pixels in the corrected frame is reduced based on a respective location of the pixels in the corrected frame.

Abstract: An article includes a first ophthalmic lens including a first spectral filter (e.g., a reflective or absorptive spectral filter), and a second ophthalmic lens including a second spectral filter (e.g., a reflective or absorptive spectral filter). The first spectral filter substantially blocks visible light having wavelengths corresponding to a first portion of a spectral sensitivity range of a first type of cone (e.g., S, M, or L cone) and substantially passes visible light having wavelengths in a second, non-overlapping portion of the spectral sensitivity range. The second spectral filter substantially blocks visible light having wavelengths in the second portion of the spectral sensitivity range and substantially passes visible light having wavelengths in the first spectral sensitivity range.

Abstract: An ophthalmic lens that includes a lens material having two opposing curved surfaces, the curved surfaces defining a lens axis; and a light scattering region surrounding a clear aperture. The clear aperture and the light scattering region are substantially centered on the lens axis, and the light scattering region has a plurality of spaced apart scattering centers (e.g., on a lens surface and/or embedded in the lens material) sized and shaped to scatter incident light, the scattering centers being arranged in a pattern that includes a random variation in spacing between adjacent dots and/or a random variation in dot size.

Abstract: A method and an apparatus for modifying initial image data for a frame based on a relative level of stimulation of cones in a viewer's eye are disclosed, wherein the modified image data results in reduced contrast between neighboring cones in the viewer's eye.

Abstract: Techniques for evaluating and reducing myopiagenic effects of electronic displays are disclosed.

Abstract: The present disclosure provides polynucleotide cassettes, expression vectors and methods for the expression of a gene in cone cells.

Abstract: The present disclosure provides compositions and methods for the prevention or treatment of ocular neovascularization, such as AMD, in a human subject, by administering subretinally a pharmaceutical composition comprising a pharmaceutically effective amount of a vector comprising a nucleic acid encoding soluble Fms-related tyrosine kinase-1 (sFlt-1) protein to the human subject.

Abstract: The present disclosure provides compositions and methods for the prevention or treatment of ocular neovascularization, such as AMD, in a human subject, by administering subretinally a pharmaceutical composition comprising a pharmaceutically effective amount of a vector comprising a nucleic acid encoding soluble Fms-related tyrosine kinase-1 (sFlt-1) protein to the human subject.

Abstract: The present disclosure provides compositions and methods for the prevention or treatment of ocular neovascularization, such as AMD, in a human subject, by administering subretinally a pharmaceutical composition comprising a pharmaceutically effective amount of a vector comprising a nucleic acid encoding soluble Fms-related tyrosine kinase-1 (sFlt-1) protein to the human subject.

Abstract: Methods for displaying an e-book using a combination of colors for text and background that have a reduced myopiagenic effect compared to black text on white background, include: presenting a user with one or more combinations of colors for the text and background identified as having a reduced myopiagenic effect, wherein none of the presented combinations comprise either black or white text or either black or white background, and, when viewed by the user's retina, an image composed of text and background rendered in any of the presented color combinations provides reduced center-surround contrast on the user's retina compared to the image viewed as black text on white background; receiving a selection of one of the color combinations from the user; and displaying the e-book file using the combination of colors for the text and background selected by the user.

Abstract: The present disclosure provides compositions and methods for the prevention or treatment of ocular neovascularization, such as AMD, in a human subject, by administering subretinally a pharmaceutical composition comprising a pharmaceutically effective amount of a vector comprising a nucleic acid encoding soluble Fms-related tyrosine kinase-1 (sFlt-1) protein to the human subject.